Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Illumina Awarded $26.7m In Patent Row

Executive Summary

The verdict resolves an intellectual property dispute in which Illumina alleged Ariosa was violating Illumina's patents on prenatal genetic testing technology.

You may also be interested in...



One in the eye for Illumina as Roche buys prenatal test maker

Roche has acquired Ariosa Diagnostics, a privately-held US developer of blood tests used to detect Down syndrome and genetic abnormalities in the foetus.

Third-Party Labs May Produce False Data, FDA Warns

The US agency is warning manufacturers about an alarming device submission trend toward unreliable data generated by third-party labs.

News We’re Watching: CDRH’s Maisel Announces Retirement, Fresenius Clearance, Philips and Smiths Recalls

This week, a device center stalwart prepared to say goodbye; the FDA cleared Fresenius's 5008X Hemodialysis System; and class I recalls for Smiths Medical and Philips Imaging were announced. 

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT122109

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel